Welcome to our dedicated page for Bristol-Myers Squibb Co news (Ticker: BMY), a resource for investors and traders seeking the latest updates and insights on Bristol-Myers Squibb Co stock.
Bristol Myers Squibb (NYSE: BMY) generates frequent news across drug development, regulatory milestones, clinical data and corporate actions, reflecting its role as a global biopharmaceutical company focused on serious diseases. News coverage on this page centers on how the company’s cardiovascular, oncology, hematology, immunology and neuroscience programs progress from clinical trials to regulatory decisions and real-world use.
Recent updates have highlighted positive Phase 3 trial results for Camzyos (mavacamten) in adolescents with symptomatic obstructive hypertrophic cardiomyopathy in the SCOUT-HCM study, including statistically significant improvements in left ventricular outflow tract gradients and safety findings consistent with adult experience. Other headlines feature regulatory developments such as the U.S. Food and Drug Administration granting priority review to an Opdivo (nivolumab) plus chemotherapy combination for previously untreated advanced classical Hodgkin lymphoma, and the FDA’s approval of Breyanzi (lisocabtagene maraleucel; liso-cel) for adults with relapsed or refractory marginal zone lymphoma.
Investors and followers of BMY can also expect news on hematology research presented at major medical meetings, including data on investigational targeted protein degradation agents like golcadomide and BMS-986458, and long-term follow-up results for Breyanzi in large B-cell and follicular lymphomas. Corporate and financial items appear as well, such as dividend declarations, debt offerings, tender offers for outstanding notes, and presentations at healthcare investment conferences.
This news feed brings together company press releases, clinical trial readouts, regulatory updates, access and affordability agreements, and SEC-reported events. For users tracking BMY stock, it offers a single place to review how Bristol Myers Squibb’s pipeline, marketed products and capital markets activity evolve over time. Bookmark this page to quickly review new trial results, FDA decisions, access initiatives and financial disclosures related to Bristol Myers Squibb.
Bristol Myers Squibb (NYSE: BMY) announced accepted amounts and pricing for its previously announced tender offers for multiple series of outstanding notes. Bristol Myers Squibb set the Amended Pool 1 Maximum at approximately $3.99 billion and the Amended Pool 2 Maximum at approximately $3.51 billion. All Pool 1 Notes and Pool 2 Notes with acceptance priority levels 1–4 tendered by the Early Tender Deadline were accepted in full; the company accepted $250,000,000 of 5.900% 2033 Notes on a prorated basis (approx. 50.84% proration).
The Early Settlement Date is November 20, 2025, and accepted Notes will be cancelled and retired.
Bristol Myers Squibb (NYSE: BMY) reported early participation results for its tender offers as of 5:00 p.m. on November 17, 2025.
The company amended Pool 1 and Pool 2 maximums: Pool 1 maximum decreased to accept all Pool 1 Notes validly tendered; Pool 2 maximum increased to accept all Pool 2 Notes with acceptance priority 1–4 and up to $250,000,000 of 5.900% Notes due 2033. The Early Settlement Date is November 20, 2025; Offers expire on December 3, 2025 if not earlier terminated.
Principal amounts tendered by series are listed and Bristol Myers Squibb expects no final settlement or additional acceptances after the Early Tender Deadline.
Bristol Myers Squibb (NYSE:BMY) and Johnson & Johnson announced discontinuation of the Phase 3 Librexia ACS trial after an Independent Data Monitoring Committee (IDMC) preplanned interim analysis determined the study is unlikely to meet its primary efficacy endpoint.
No new safety concerns were identified and the safety profile remained consistent with prior milvexian studies. The IDMC recommended that the other Phase 3 studies in the Librexia program—Librexia AF and Librexia STROKE—continue as planned, with topline data expected in 2026.
Sarah Cannon Research Institute and Bristol Myers Squibb (NYSE: BMY) expanded a strategic collaboration to accelerate oncology clinical trial enrollment and broaden access to trials in U.S. communities. The partnership centers on SCRI’s Accelero delivery model across 200+ locations and 1,300 physicians in 20+ states to embed BMY trials in community settings.
Early results cited a 45% reduction in study startup timelines across eight BMY trials at SCRI sites versus non-SCRI sites, with the collaboration emphasizing data-driven enrollment, equity, and faster patient access to investigational cancer therapies.
Bristol Myers Squibb (NYSE: BMY) priced a public offering of senior unsecured notes totaling €5.0 billion across five tranches with maturities from 2030 to 2055 and coupons ranging from 2.973% to 4.581%. The notes will be issued by BMS Ireland Capital Funding DAC and fully guaranteed on a senior unsecured basis by Bristol-Myers Squibb Company.
The company expects closing on November 10, 2025, subject to customary conditions. Net proceeds, together with approximately $3.0 billion of cash on hand, are intended to fund a tender offer and other repurchases/repayments, pay fees and expenses, and, if any remains, for general corporate purposes.
Bristol Myers Squibb (NYSE: BMY) will present new long‑term and real‑world cardiovascular data at the American Heart Association Scientific Sessions 2025 (Nov 7–10, 2025).
Key highlights include nearly four years of EXPLORER‑LTE long‑term extension data for Camzyos (mavacamten), ~34 months of REMS real‑world safety data, and analyses of hospital/ER rates, monotherapy effectiveness across global cohorts, and ODYSSEY‑HCM results.
Camzyos is approved in more than 50 countries and prescribed in the U.S. by >4,000 clinicians to >20,000 patients; safety details include LVEF changes and specific adverse event rates reported in trials.
Bristol Myers Squibb (NYSE: BMY) commenced cash tender offers on November 3, 2025 to purchase specified outstanding notes in two pools: Pool 1 (up to $4,000,000,000 aggregate purchase price) and Pool 2 (up to $3,000,000,000 aggregate purchase price).
Key mechanics: Early Tender Deadline is November 17, 2025; Price Determination Date is November 18, 2025; Expiration Date is December 3, 2025. Early tender premium is $50 per $1,000 and Total Consideration includes fixed spreads to specified U.S. Treasury yields. Offers are conditioned on a Finance Sub new notes offering plus approximately $3.0 billion of BMS cash to fund purchases.
Bristol Myers Squibb (NYSE: BMY) reported third quarter 2025 financial results and will host a conference call and live audio webcast for analysts and investors at 8:00 a.m. ET on October 30, 2025. Detailed Q3 2025 earnings press release and investor presentation are available on the company’s Investor Relations website.
A replay of the webcast will be available on the Investor Relations site approximately three hours after the conference call concludes. Media and investor contact emails are provided for follow-up information.
Bristol Myers Squibb (NYSE:BMY) reported Week 52 data from the pivotal Phase 3 POETYK PsA-1 trial showing sustained efficacy and a consistent safety profile for Sotyktu (deucravacitinib) in adults with active psoriatic arthritis.
Key results: ACR20 at Week 16 was 54.2% (placebo 34.1%, p<0.0001) and was maintained at Week 52 at 63.1%; patients switched from placebo reached 60.8% at Week 52. Radiographic no-progression rates: 82.0% (Sotyktu) vs 71.5% (placebo) at Week 16; sustained through Week 52. Integrated Phase 2 PAISLEY-SLE/LTE data showed durable efficacy and consistent safety with up to 4 years exposure. Regulatory reviews are ongoing; FDA PDUFA goal date: March 6, 2026.
Bristol Myers Squibb (NYSE: BMY) presented updated Phase 1 Breakfree-1 data (Oct 25, 2025) for autologous CD19 NEX-T CAR T therapy BMS-986353 in systemic sclerosis (SSc), systemic lupus erythematosus (SLE) and idiopathic inflammatory myopathies (IIM).
Across 71 treated patients, results show robust CAR T expansion, complete B cell depletion and a potential immune reset; 94% of evaluable patients remained off chronic immunosuppressive therapy at analysis. Key cohort results: SSc pFVC median +10% at six months (ILD subgroup); SLE: 92% off SLE-specific ISTs and DL1 selected as RP2D; IIM: 91% achieved moderate-major responses. Safety: mostly transient, early TEAEs with some grade 3 ICANS/CRS events that resolved.